IDN-6556-14 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
February 15, 2017
Gastroenterology - Stomach
Principal Investigator: Stuart C Gordon, MD
The purpose of this research study is to test whether a drug called emricasan (IDN-6556) can lower severe portal hypertension due to non-alcoholic steatohepatitis (NASH).
Please contact us for a full list of criteria.